Clinical trials: Rising costs limit innovation

Annals of Neurology

Volumn 62, Issue 6, 2007, Pages

  Johnston, S Claiborne ^a   Hauser, Stephen L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; STATINE DERIVATIVE;

ALZHEIMER DISEASE; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; EDITORIAL; EXPANDED DISABILITY STATUS SCALE; HEALTH CARE COST; HEALTH CARE DELIVERY; HUMAN; MULTIPLE SCLEROSIS; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; OUTPATIENT; PRIORITY JOURNAL; RANKIN SCALE; REIMBURSEMENT; SENILE PLAQUE; UNIFIED PARKINSON DISEASE RATING SCALE;

CLINICAL TRIALS AS TOPIC; COSTS AND COST ANALYSIS; HUMANS;

EID: 37849047965     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.21329     Document Type: Editorial

References (5)

1. Adams CP, Brantner VV. Estimating the cost of new drug development: is it really 802 million dollars? Health Aff (Millwood) 2006;25:420-428.
2. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003;22:151-185.
3. Wood AJJ. A proposal for radical changes in the drug-approval process. New Engl J Med 2006;355:618.
4. Burman W, Breese P, Weis S et al. The effects of local review on informed consent documents from a multicenter clinical trials consortium. Control Clin Trials 2003;24:245-255.
5. Burman WJ, Reves RR, Cohn DL, Schooley RT. Breaking the camel's back: multicenter clinical trials and local institutional review boards. Ann Intern Med 2001;134:152-157.